<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip G Janicak, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H182696693">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for treating mania was discovered in 1949, making it the first medication specifically developed to treat bipolar disorder [
         <a href="#rid1">
          1
         </a>
         ]. Lithium remains a mainstay of treatment for bipolar disorder, especially for acute mania and maintenance treatment [
         <a href="#rid2">
          2
         </a>
         ]. In addition, lithium appears to reduce the risk of suicide in patients with bipolar disorder [
         <a href="#rid2">
          2-4
         </a>
         ], and may possibly have other benefits, such as reducing the risk of developing neurocognitive disorder [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16645.html" rel="external">
          "Geriatric bipolar disorder: Maintenance treatment", section on 'Cognitive impairment'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is the third element of the periodic table and shares certain properties with other monovalent cations such as potassium and sodium, as well as the divalent cations calcium and magnesium [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         The pharmacology, administration, and management of adverse effects of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         are reviewed here. Choosing a medication (including lithium) to treat acute mania, hypomania, and bipolar depression is discussed separately, as is the choice of medication for maintenance treatment of bipolar disorder, and the epidemiology, clinical manifestations, and diagnosis of bipolar disorder.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/678.html" rel="external">
          "Bipolar disorder in adults: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         to treat unipolar major depression is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13506.html" rel="external">
          "Unipolar depression in adults: Treatment with lithium"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H136818786">
         <span class="h1">
          DEFINITION OF BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is a mood disorder that is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H385746629">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         ’s mechanism of action in treating mania is unknown. However, reviews suggest that the overall effect of lithium is such that it stimulates inhibitory neurotransmission and inhibits excitatory transmission [
         <a href="#rid10">
          10,11
         </a>
         ]. As an example, multiple studies suggest that some neurons in patients with bipolar disorder may be hyperexcitable (more easily stimulated) and that lithium may reduce this hyperexcitability in patients who respond to the drug [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         One hypothesis regarding
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ’s specific therapeutic effects is that it inhibits the activity of glycogen synthase kinase 3 beta, which is involved in gene transcription and regulates an intracellular signaling peptide called Wnt [
         <a href="#rid10">
          10,11
         </a>
         ]. Other hypotheses are that lithium works by depleting inositol in the central nervous system and thus dampens neurotransmission dependent upon this second messenger [
         <a href="#rid10">
          10,11
         </a>
         ], or that lithium inhibits overactive protein kinase C intracellular signaling [
         <a href="#rid10">
          10,11,13
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         appears to affect multiple neurotransmitter systems including norepinephrine, dopamine, serotonin, and gamma aminobutyric acid; and second messenger systems including cyclic adenosine monophosphate and cyclic guanosine monophosphate [
         <a href="#rid10">
          10,11,14
         </a>
         ]. Other studies also implicate glutamate-induced excitotoxicity in the pathogenesis of bipolar disorder (particularly mania), and hypothesize that lithium’s efficacy may be related to its modulation of abnormal calcium activity at the N-methyl-D-aspartate ionotropic receptor [
         <a href="#rid11">
          11,15
         </a>
         ]. This is further supported by the antidepressant and antisuicidal effects of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         in bipolar and unipolar depression, an agent which acts as an antagonist at the N-methyl-D-aspartate receptor. (See
         <a class="medical medical_review" href="/z/d/html/115481.html" rel="external">
          "Bipolar major depression in adults: Investigational and nonstandard approaches to treatment", section on 'Ketamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119992.html" rel="external">
          "Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects"
         </a>
         .)
        </p>
        <p>
         In addition,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         also appears to increase neurogenesis and neuroprotective factors, and in patients with bipolar disorder, may preserve or increase cortical gray matter, white matter integrity, and limbic structures such as the hippocampus, thalamus, and amygdala [
         <a href="#rid16">
          16-24
         </a>
         ]. As an example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 15 magnetic resonance imaging studies compared gray matter volume in patients with bipolar disorder who either were treated with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (n = 368) or were not (n = 486) [
         <a href="#rid25">
          25
         </a>
         ]. Gray matter volume was greater in lithium treated patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study found that hippocampal volumes were smaller in bipolar patients who were never exposed to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (n = 15), compared with healthy controls (n = 15) and patients who were exposed for more than two years (n = 15); hippocampal volumes were comparable for the controls and the patients exposed to lithium for more than two years [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The neuroprotective effects of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         may be the result of direct neurochemical effects, rather than indirect effects secondary to treatment or prevention of mood episodes [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Response to long-term treatment with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (eg, decreased recurrences) may involve genetic factors [
         <a href="#rid28">
          28
         </a>
         ]. A genome-wide association study of patients with bipolar disorder (n &gt;2500), who were treated with lithium monotherapy for a minimum of six months, found that four linked single nucleotide polymorphisms on chromosome 21 were associated with a good response to lithium [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H446684325">
         <span class="h1">
          ROLE IN TREATING BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         The three primary considerations in choosing a medication are clinical efficacy, tolerability, and safety. These factors involve issues such as past response to medications, comorbid medical illnesses, concurrent medications, and specific symptoms. Another consideration is cost.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is one of many medications that can be selected to treat acute mania, hypomania, and bipolar and unipolar depression in adults (as well as children and adolescents), and is also a potential choice for maintenance treatment of bipolar disorder. The choice of pharmacotherapy for bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is generally avoided in patients with significant renal disease and often not used during the first trimester of pregnancy. In addition, lithium can significantly affect thyroid function. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H446684335">
         <span class="h2">
          Reduced risk of suicide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term treatment with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is associated with a reduced risk of suicide attempts and suicide deaths. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Reduced risk of suicide'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H446684351">
         <span class="h2">
          Severely ill patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe mania, the combination of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus an antipsychotic is often useful [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Severe manic episodes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H446684761">
         <span class="h1">
          PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The absorption, distribution, and elimination of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         are well described [
         <a href="#rid32">
          32-34
         </a>
         ]. Lithium is rapidly absorbed through the gastrointestinal tract; food does not alter lithium absorption [
         <a href="#rid10">
          10,35
         </a>
         ]. Peak serum levels occur in one to two hours with standard, immediate-release preparations of lithium and within four to five hours with slow-release preparations. Absorption of immediate-release lithium is complete within six to eight hours, and for slow-release preparations in approximately 8 to 12 hours. Lithium is not protein bound and is distributed throughout total body water. Brain levels are highest within two hours of peak serum levels. Steady state is achieved within four to five days after the last dose change.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is not metabolized and is excreted almost exclusively through the kidneys [
         <a href="#rid10">
          10
         </a>
         ]. Thus, lithium’s elimination half-life is determined primarily by renal function. The half-life in healthy young patients is approximately 24 hours and increases as renal function declines with age.
        </p>
        <p class="headingAnchor" id="H1520353406">
         <span class="h1">
          CONTRAINDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is contraindicated in patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant renal impairment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium depletion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dehydration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant cardiovascular disease
        </p>
        <p>
        </p>
        <p>
         Renal impairment, sodium depletion, and dehydration increase the risk of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity. In addition, lithium can rarely cause sinus node dysfunction (eg, sinus bradycardia and sinoatrial block), atrioventricular node dissociation with atrioventricular block and junctional rhythms, and ventricular premature beats.
        </p>
        <p>
         Psoriasis, which
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exacerbates, is a relative contraindication.
        </p>
        <p class="headingAnchor" id="H182696749">
         <span class="h1">
          PRESCRIBING LITHIUM
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several basic points to discuss with patients before prescribing
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , including potential side effects, the need to take the medication as prescribed rather than on as-needed basis, and to expect that response and remission may not occur until a few days to weeks have elapsed after a therapeutic dose/level has been achieved.
        </p>
        <p class="headingAnchor" id="H182696765">
         <span class="h2">
          Lithium dose and serum concentrations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The starting dose of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is usually 300 mg two or three times daily [
         <a href="#rid36">
          36-39
         </a>
         ]. The total daily dose is then increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. Dose increases generally occur more frequently at the beginning of treatment and less often as clinicians approach the target dose.
        </p>
        <p>
         The half-life of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is approximately 24 hours. Thus, it takes at least four or five days for serum lithium concentrations to reach steady state after the dose is changed.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         can be dosed either once daily or in a divided dose regimen. Clinicians should start with a twice daily or three times daily dosing schedule to minimize side effects (especially nausea) early in treatment and consolidate the dose schedule to once daily after a number of weeks or months of treatment. Some patients may have to continue taking lithium in two or four divided doses to minimize peak level side effects. However, adherence generally decreases as the frequency of dosing increases [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         The target serum level for acute phase management and maintenance treatment is between 0.8 and 1.2 mEq/L (0.8 and 1.2 mmol/L), and levels should usually not exceed 1.2 mEq/L (1.2 mmol/L) [
         <a href="#rid39">
          39
         </a>
         ]. Patients who cannot tolerate a level of 0.8 mEq/L (0.8 mmol/L) may respond to a level of 0.6 mEq/L (0.6 mmol/L) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         After reaching the estimated therapeutic dose range (generally 900 mg to 1800 mg per day), the serum
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         concentration should be checked. Subsequently, a level should be measured five to seven days after each dose increase. In addition, if the dose is not changed and a level not checked for two or more weeks, a level should be checked before increasing the dose. An office-based instrument for fingerstick tests of lithium levels is available [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         levels should be drawn approximately 12 hours after the last dose (12-hour serum trough level) and generally collected in the morning, before the first dose of the day. Changes in the serum level per unit time are not dramatic 12 hours after the last dose. Thus, a level drawn 11 to 13 hours after the last dose, or even 10 to 14 hours, provides meaningful information. In contrast, a serum level drawn a few hours after lithium ingestion is subject to marked fluctuation if the level is drawn one hour sooner or later, leading to unreliable information.
        </p>
        <p>
         Serum
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         levels are closely related to renal function, salt balance, and water balance. Clinicians can expect lithium concentrations to change as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dehydration (may occur with gastrointestinal viral infections or high fever) causes higher
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing sodium intake causes increased sodium and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         excretion and lower lithium levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased sodium intake causes sodium and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         reabsorption in the proximal tubule and an increase in serum lithium levels.
        </p>
        <p>
        </p>
        <p>
         When
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is taken once per day, serum concentrations are approximately 25 percent higher compared with levels that are observed when lithium is taken two or three times per day; this is due to changes in renal excretion [
         <a href="#rid43">
          43
         </a>
         ]. Therefore, a once daily lithium level of 1.0 mEq/L (1.0 mmol/L) is expected to drop to a level of 0.8 mEq/L (0.8 mmol/L) if the patient switches to a divided dose regimen. Virtually all studies examining optimal lithium levels have used divided dose regimens.
        </p>
        <p class="headingAnchor" id="H446684831">
         <span class="h3">
          Older adult patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         in older adult patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16446.html" rel="external">
          "Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H182696772">
         <span class="h2">
          Lithium preparations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple preparations of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         are available, varying in dose from 100 to 1000 mg. There is no difference in treatment efficacy or serum concentrations among the various lithium preparations.
        </p>
        <p>
         The most commonly prescribed preparation in the United States contains 300 mg of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         carbonate, which provides 8 mEq (8 mmol) of lithium. Lithium carbonate is available as a tablet or capsule. In addition, lithium is available in some countries (other than the United States) as a liquid in the form of lithium citrate for patients who have difficulty swallowing pills. A dose of 5 mL contains 8 mEq of lithium and is equivalent in strength to 300 mg of lithium carbonate.
        </p>
        <p>
         Several slow-release
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         tablets are available. Slow-release lithium may cause less nausea than conventional, immediate-release forms at least in the beginning of treatment, but also a slightly higher incidence of diarrhea, due to more distal gastrointestinal absorption. Slow-release tablets should be swallowed whole, rather than crushed or chewed.
        </p>
        <p>
         Additional information about
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         preparations is discussed separately.
        </p>
        <p class="headingAnchor" id="H182696786">
         <span class="h2">
          Lithium toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         levels can lead to toxicity with severe side effects and multisystem dysfunction that can be fatal if not recognized. Lithium toxicity is a clinical diagnosis that is confirmed by serum lithium levels [
         <a href="#rid36">
          36
         </a>
         ]. Relatively mild toxicity usually does not occur until serum lithium reaches a level of 1.5 mEq/L (1.5 mmol/L). Levels ≥2.5 mEq/L (2.5 mmol/L) constitute a medical emergency, even in patients who appear relatively asymptomatic. Symptoms and treatment of toxicity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         has a narrow therapeutic index, which means that the dose at which it is clinically effective is only slightly lower than the dose at which it becomes toxic [
         <a href="#rid44">
          44
         </a>
         ]. Many patients thus suffer an episode of lithium toxicity. As an example, a retrospective study of patients (n = 1340) prescribed lithium found that at least one episode of lithium levels ≥1.5 mmol/L occurred in 7 percent [
         <a href="#rid45">
          45
         </a>
         ]. Although acute kidney injury (creatinine ≥26.5 micromole/L/48 hours) occurred in 34 percent of the episodes, renal function returned to baseline in each instance. No fatalities occurred.
        </p>
        <p>
         The likelihood of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         intoxication is increased when lithium excretion is impaired. This most commonly occurs with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underlying renal insufficiency
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Effective volume depletion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older adult patients (low glomerular filtration rate)
        </p>
        <p>
        </p>
        <p>
         Drug-drug interactions are another risk factor for
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity. A retrospective study identified patients taking lithium who either utilized acute care services (eg, emergency department) for lithium toxicity (n = 50) or did not (n = 250) [
         <a href="#rid46">
          46
         </a>
         ]. Patients who suffered lithium toxicity were far more likely to have started a medication that can interact with lithium, compared with patients without lithium toxicity (odds ratio 30).
        </p>
        <p class="headingAnchor" id="H182696793">
         <span class="h2">
          Drug interactions with lithium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications that change renal function, salt balance, or water balance can alter
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         excretion and serum lithium concentrations. Lithium levels must be closely monitored in patients taking these medications. These drug interactions are as follows [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increases
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         level
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thiazide diuretics
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nonsteroidal anti-inflammatory drugs except
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Angiotensin converting enzyme inhibitors
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibiotics tetracyclines and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreases
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         level
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Potassium-sparing diuretics
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sodium-glucose cotransporter 2 (SGLT2) inhibitors
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          Theophylline
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         May increase or decrease
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         level
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Loop diuretics
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Calcium channel blockers
        </p>
        <p>
        </p>
        <p>
         These medications are not contraindicated for patients taking
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . Rather, patients receiving medications that may interact with lithium should have their serum levels monitored more closely. Specific interactions of any particular drug with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p class="headingAnchor" id="H182696800">
         <span class="h2">
          Laboratory tests and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before prescribing
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and during ongoing treatment, laboratory tests need to be obtained because lithium can adversely affect several organ systems. Management of abnormal test results and adverse effects resulting from lithium are described elsewhere in the topic, as is management of a positive pregnancy test. (See
         <a class="local">
          'Renal'
         </a>
         below and
         <a class="local">
          'Thyroid'
         </a>
         below and
         <a class="local">
          'Parathyroid'
         </a>
         below and
         <a class="local">
          'Cardiac'
         </a>
         below and
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p>
         Prior to beginning
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , the following tests should be obtained [
         <a href="#rid47">
          47-51
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis, blood urea nitrogen, creatinine, thyroid function studies, and calcium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test for women of childbearing potential.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram for patients with risk factors for coronary heart disease, including diabetes mellitus, hypertension, dyslipidemia, and cigarette smoking. (See
         <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">
          "Overview of established risk factors for cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         levels should be checked five to seven days after the dose is changed. In addition, a lithium level should be checked if a dose increase is under consideration and a level has not been measured for at least two weeks. Patients on steady doses should have their levels checked every 6 to 12 months.
        </p>
        <p>
         In addition to checking
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         levels during ongoing treatment, renal, thyroid, and parathyroid function should be monitored as follows [
         <a href="#rid10">
          10,44,47-51
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis, blood urea nitrogen, and creatinine every two to three months during the first six months of therapy, and every 6 to 12 months thereafter. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid function tests once or twice during the first six months, and every 6 to 12 months thereafter or more frequently in higher risk patients. (See
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum calcium is monitored yearly.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H182696807">
         <span class="h1">
          MANAGING LITHIUM ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         can cause many acute and long-term adverse effects that are not necessarily associated with toxicity [
         <a href="#rid52">
          52
         </a>
         ]. Some adverse effects, such as weight gain and cognitive impairment, are more likely to be associated with nonadherence than other adverse effects, such as nausea, polyuria/polydipsia, and tremor [
         <a href="#rid44">
          44
         </a>
         ]. Severe or a sudden worsening of side effects may be a sign of lithium toxicity. (See
         <a class="local">
          'Lithium toxicity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3160417336">
         <span class="h2">
          General strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         General strategies for managing adverse effects of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         include [
         <a href="#rid44">
          44
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Watchful waiting – Tolerance to some side effects (eg, nausea and tremor) can eventually occur, but is unlikely with other adverse effects (eg, weight gain).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Changing the time of administration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lowering the dose; however, dose reductions risk compromising efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Changing to a different
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         formulation (immediate or slow release).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dividing the daily dose to take smaller amounts more often, to decrease peak serum levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treating adverse effects with a second drug (eg, diuretic for polyuria/polydipsia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discontinuing
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and switching to a different drug if adverse effects are intolerable and cannot be managed.
        </p>
        <p>
        </p>
        <p>
         Strategies for managing specific adverse effects are discussed in the sections below.
        </p>
        <p class="headingAnchor" id="H68178733">
         <span class="h2">
          Renal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal function is adversely affected by
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and thus monitored with laboratory tests [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="local">
          'Laboratory tests and monitoring'
         </a>
         above.)
        </p>
        <p>
         Adverse renal effects are often functional and reversible, but may eventually progress to structural, permanent changes [
         <a href="#rid44">
          44,53,54
         </a>
         ]. As an example, a study examined the impact of long-term
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         treatment (mean duration 18 years) on glomerular filtration rate in 312 bipolar disorder patients (mean age = 56 years) [
         <a href="#rid55">
          55
         </a>
         ]. Extended lithium exposure reduced the estimated glomerular filtration rate by approximately 30 percent more than that associated with aging alone. Additional risk factors for decreased estimated glomerular filtration rate were higher serum lithium concentrations, longer exposure, lower initial estimated glomerular filtration rate, general medical comorbidity, and older age. None of the patients developed end-stage kidney disease.
        </p>
        <p>
         Abnormal renal function tests are managed in collaboration with a nephrologist to determine the need for further testing, a reduction in the dose of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , or switching to an alternative medication for treating bipolar disorder. Additional information about lithium and renal toxicity is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2429139961">
         <span class="h3">
          Polyuria and polydipsia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyuria is often defined as urinating more than three liters in 24 hours [
         <a href="#rid44">
          44
         </a>
         ]. Polyuria and polydipsia have been observed in up to 70 percent of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         treated patients; potential risk factors include longer duration of treatment, higher serum lithium concentrations, episodes of lithium toxicity, and use of other psychotropic medications. Polyuria and polydipsia may be a symptom of arginine vasopressin resistance (previously called nephrogenic diabetes insipidus). (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium", section on 'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'
         </a>
         .)
        </p>
        <p>
         Clinicians should attempt to prevent polyuria at the onset of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         treatment by [
         <a href="#rid44">
          44
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administering
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         once per day
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintaining
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         serum concentrations as low as possible
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding episodes of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity
        </p>
        <p>
        </p>
        <p>
         For patients who develop polyuria, diuretics (eg, the potassium-sparing diuretic
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         ) may decrease polyuria, but caution must be used because many diuretics alter serum
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         concentrations; lithium doses may need to be adjusted and lithium levels checked more often [
         <a href="#rid44">
          44
         </a>
         ]. Use of diuretics that decrease potassium levels necessitates measuring potassium levels and possibly administering potassium supplements.
        </p>
        <p>
         Specific interactions of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p class="headingAnchor" id="H68178740">
         <span class="h2">
          Thyroid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid function is adversely affected by
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and thus monitored with laboratory tests (see
         <a class="local">
          'Laboratory tests and monitoring'
         </a>
         above); lithium can cause goiter, hypothyroidism, chronic autoimmune thyroiditis, and possibly hyperthyroidism. The adverse effects of lithium on thyroid function and their management are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         .)
        </p>
        <p>
         Neither pretreatment hypothyroidism (presumably treated adequately with T4) nor lithium-induced hypothyroidism is a contraindication to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         therapy [
         <a href="#rid44">
          44,56
         </a>
         ]. Reasonable recommendations are to monitor serum thyrotropin and if it rises much above the upper value of normal, to start T4 while continuing the lithium. Consultation with an endocrinologist may also be indicated. (See
         <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">
          "Clinical manifestations of hypothyroidism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H68178747">
         <span class="h2">
          Parathyroid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         may cause hypercalcemia, elevated serum parathyroid hormone, and hyperparathyroidism [
         <a href="#rid44">
          44,50
         </a>
         ]. Patients with lithium-induced hypercalcemia and hyperparathyroidism are generally asymptomatic [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         An elevated calcium level should prompt a serum parathyroid hormone concentration. If the hormone level is abnormal, an endocrine consult is obtained. Hypercalcemia, hyperparathyroidism secondary to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and measurement of serum calcium are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2038.html" rel="external">
          "Primary hyperparathyroidism: Pathogenesis and etiology", section on 'Lithium therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">
          "Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation", section on 'Serum calcium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">
          "Primary hyperparathyroidism: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3415726162">
         <span class="h2">
          Tremor
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         tremor is common; pooled results from multiple studies suggest that the prevalence is approximately 25 percent [
         <a href="#rid58">
          58
         </a>
         ]. The pathogenesis may involve lithium-induced accumulation of iron in the substantia nigra [
         <a href="#rid59">
          59
         </a>
         ]. Tremor secondary to lithium is classified as an action tremor, and subcategorized as an exaggerated physiologic tremor. Lithium tremors are also subclassified as a postural tremor that occurs when a specific posture, such as holding the arms outstretched or while standing, is voluntarily maintained. (See
         <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">
          "Overview of tremor"
         </a>
         .)
        </p>
        <p>
         Onset of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         tremor typically occurs when the drug is started or titrated up, but tremor can appear at any time during treatment [
         <a href="#rid44">
          44,58
         </a>
         ]. Lithium tremor is generally symmetric, limited to the hands or upper limbs, and nonprogressive. The frequency of the involuntary rhythmic oscillation of the hands is approximately 10 Hertz. Factors that increase the risk of tremor include higher lithium doses and serum concentrations, anxiety, caffeine, medications (eg, antiarrhythmics, beta-adrenergic agents,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         ), emotional and physical stress, fatigue, and older age.
        </p>
        <p>
         The differential diagnosis of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         tremor includes metabolic abnormalities, benign essential tremor, Parkinson disease, and lithium toxicity [
         <a href="#rid58">
          58
         </a>
         ]. Tremor caused by lithium toxicity is more coarse and severe than is otherwise observed in patients treated with lithium; in addition, lithium toxicity may affect body parts other than the upper extremity, and is likely to occur with other symptoms of toxicity. (See
         <a class="local">
          'Lithium toxicity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning", section on 'Signs and symptoms'
         </a>
         .)
        </p>
        <p>
         Clinicians evaluating
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         tremor should obtain a history, physical examination, and laboratory tests (including a serum lithium concentration), to rule out other causes of tremor [
         <a href="#rid58">
          58
         </a>
         ]. Additional information about the evaluation of lithium tremor is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">
          "Overview of tremor", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
         Watchful waiting is a reasonable approach to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         tremor because it often is relatively mild and resolves over time [
         <a href="#rid44">
          44,58
         </a>
         ]. Management of lithium tremor that is troublesome and/or persistent starts with modifying aggravating factors (eg, decreasing caffeine intake). In addition, it may help to change the lithium preparation from long acting to short acting, or to a different salt (ie, from carbonate to citrate), or to divide the daily dose to take smaller amounts more often.
        </p>
        <p>
         For
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         tremor that still persists and causes moderate to severe functional problems, we suggest add-on pharmacotherapy (eg, beta blockers such as
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ) [
         <a href="#rid44">
          44,58
         </a>
         ]. Alternatively, the total daily dose of lithium can be reduced if feasible. Choosing and administering add-on pharmacotherapy for lithium tremor is discussed separately in the context of essential tremor. (See
         <a class="medical medical_review" href="/z/d/html/4898.html" rel="external">
          "Essential tremor: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H124043424">
         <span class="h2">
          Nausea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nausea secondary to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is observed in 10 to 20 percent of patients [
         <a href="#rid44">
          44
         </a>
         ]. Management strategies include the following, listed from most to least preferable:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Taking
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with food or after meals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using a sustained release formulation of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (to decrease peak serum concentrations because nausea may be related to higher peak levels).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dividing the daily dose to take smaller amounts more often (to decrease peak serum concentrations).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment with a second drug. (See
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting", section on 'Antiemetics and prokinetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reducing the total daily dose.
        </p>
        <p>
        </p>
        <p>
         Nausea often abates over time, which allows patients to resume a higher dose and once daily dosing [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Vomiting secondary to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is uncommon and can indicate lithium toxicity, especially in the context of other adverse effects, such as coarse tremor and ataxia [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Lithium toxicity'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1681164475">
         <span class="h2">
          Loose stools/diarrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lithium-induced loose stools/diarrhea is seen in up to 10 percent of patients [
         <a href="#rid44">
          44
         </a>
         ]. Higher serum
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         concentrations (eg, greater than 0.8 mEq/L [0.8 mmol/L]) may correlate with loose stools/diarrhea; thus, management strategies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using an immediate-release formulation of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (to avoid distal absorption of the drug).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment with a second drug. (See
         <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">
          "Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'Symptomatic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reducing the daily dose.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1168214413">
         <span class="h2">
          Weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         can cause weight gain through several mechanisms, such as carbohydrate craving, increased thirst, and fluid consumption, water retention related to salt retention, and reduced metabolism secondary to hypothyroidism. A meta-analysis of five randomized trials compared lithium with placebo in patients with bipolar disorder; four trials lasted to 12 or 18 months (n = 899 patients) and one trial lasted 3 months (n = 325) [
         <a href="#rid50">
          50
         </a>
         ]. Clinically significant weight gain, defined as an increase &gt;7 percent from baseline, occurred in nearly twice as many patients treated with lithium than placebo (relative risk 1.9, 95% CI 1.3-2.8). In addition, weight gain is relatively distressing, compared with other adverse effects [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Preventing and managing weight gain during
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         treatment is based upon nonspecific measures [
         <a href="#rid44">
          44
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discussing the likelihood of weight gain at the outset of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encouraging patients to drink low caloric drinks when thirsty.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary strategies, exercise, and drug therapy. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management", section on 'Drug therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treating polyuria/polydipsia-induced weight gain with a diuretic, and treating hypothyroidism-induced weight gain with thyroid supplementation. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1864550997">
         <span class="h2">
          Cognitive impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lithium-induced cognitive impairment appears to be one of the most distressing adverse effects of the drug and often leads to nonadherence [
         <a href="#rid10">
          10,44
         </a>
         ]. Cognitive dysfunction secondary to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         needs to be distinguished from the cognitive impairment that is associated with bipolar disorder per se, including patients who are euthymic or depressed [
         <a href="#rid44">
          44,60
         </a>
         ]. Concomitant medications (eg, antipsychotics, antidepressants, and benzodiazepines) may also contribute to cognitive dulling that occurs in patients receiving lithium. In addition, it appears that the neurocognitive effects are worse at higher doses and are cumulative over time. Cognitive impairment that is due to bipolar disorder itself is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features", section on 'Cognition'
         </a>
         .)
        </p>
        <p>
         Multiple cognitive domains are adversely affected by
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . As an example, a meta-analysis of six studies included patients with remitted mood disorders (n = 326, primarily bipolar disorder) and found that use of lithium was associated with small to moderate impairment of immediate verbal learning and memory, creativity, and psychomotor performance [
         <a href="#rid61">
          61
         </a>
         ]. However, lithium may preserve other domains of neurocognition [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Management strategies include dividing the daily dose to take smaller amounts more often; in addition, lowering the dose of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         may help, because cognitive dulling may be dose related [
         <a href="#rid44">
          44
         </a>
         ]. Among patients receiving polypharmacy, especially complex psychotropic regimens that include three or more drugs, discontinuing one or more drugs may improve cognitive dysfunction without exacerbating mood symptoms. Adding stimulants such as
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         and
         <a class="drug drug_general" data-topicid="9260" href="/z/d/drug information/9260.html" rel="external">
          armodafinil
         </a>
         may possibly help, but there is no high quality evidence to support this approach.
        </p>
        <p class="headingAnchor" id="H350234682">
         <span class="h2">
          Sexual dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lithium-induced sexual dysfunction appears to be common. One study assessed clinically stable patients with bipolar disorder who were treated with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for an average of 10 years (n = 100 patients; mean age 44 years); 85 percent were receiving lithium monotherapy and the mean dose in the entire sample was 800 mg/day [
         <a href="#rid62">
          62
         </a>
         ]. Sexual dysfunction across multiple domains (eg, arousal, sexual drive, and penile erection/vaginal lubrication) was present in 37 percent and was associated with poor adherence. Risk factors for sexual dysfunction included older age and the presence of other adverse effects.
        </p>
        <p>
         Management strategies, beyond the general strategies for managing adverse effects (see
         <a class="local">
          'General strategies'
         </a>
         above), are discussed in the context of treating the general population of patients with sexual dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">
          "Treatment of male sexual dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5485.html" rel="external">
          "Overview of sexual dysfunction in females: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H68179204">
         <span class="h2">
          Cardiac
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         may rarely cause cardiac dysrhythmias in patients without pre-existing cardiac disease [
         <a href="#rid36">
          36,52,63
         </a>
         ]. In addition, lithium may lead to the following abnormalities on the electrocardiogram, which may anticipate the onset of dysrhythmias [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repolarization abnormalities of the T wave or ST segment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Findings consistent with sinus node dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/940.html" rel="external">
          "Sinus node dysfunction: Epidemiology, etiology, and natural history", section on 'Other'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An unmasked or modulated Brugada pattern. (See
         <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">
          "Brugada syndrome: Clinical presentation, diagnosis, and evaluation", section on 'Provoking factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These electrocardiogram findings should prompt a cardiology consult.
        </p>
        <p class="headingAnchor" id="H182696969">
         <span class="h1">
          PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein anomaly) [
         <a href="#rid64">
          64-66
         </a>
         ], many authorities consider the absolute risk small [
         <a href="#rid67">
          67-71
         </a>
         ]. The use of lithium during pregnancy and risks of lithium exposure during pregnancy and breastfeeding are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93451.html" rel="external">
          "Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93451.html" rel="external">
          "Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93451.html" rel="external">
          "Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H182696976">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">
          "Patient education: Bipolar disorder (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The United States National Library of Medicine and National Institutes of Health have created an educational document entitled "
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         ” that explains the use of lithium. It is available online at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmedlineplus.gov%2Fdruginfo%2Fmeds%2Fa681039.html&amp;token=d5ngiCbB8xFYJWkFI1xcekh7CTTcVcbY3fVxLXEvc7SjPG19nXVYwhTOg6yeV5KM2iMmZD8kkjn6fiueABJyGw%3D%3D&amp;TOPIC_ID=15317" target="_blank">
          the website
         </a>
         , and copies may be printed free of charge.
        </p>
        <p>
         The United States National Institute of Mental Health has a document entitled, “Mental Health Medications,” that is available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Ftopics%2Fmental-health-medications&amp;token=DUyqmXMqVzfwMQwHS0hGhjVnvSmWNYwrVIOQjil9H1c7QeKzCSx0qXlroHThkaY5AZSlsPjqMvW2SrhzIcY0ie182z2bJyFkd3seZ7M6%2Fa0%3D&amp;TOPIC_ID=15317" target="_blank">
          the website
         </a>
         , or through the toll-free number 866-615-6464. Copies may be printed free of charge.
        </p>
        <p>
         The Depression and Bipolar Support Alliance (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=15317" target="_blank">
          the website
         </a>
         or 800-826-3632) is a national organization whose mission is to educate members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.
        </p>
        <p>
         The National Alliance on Mental Illness (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=15317" target="_blank">
          the website
         </a>
         or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.
        </p>
        <p class="headingAnchor" id="H182696983">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for
         </strong>
         <strong>
          lithium
         </strong>
         <strong>
          in bipolar disorder
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is one of many medications that can be selected to treat acute mania, hypomania, and bipolar depression, and is also a potential choice for maintenance treatment of bipolar disorder. In addition, lithium may reduce the risk of suicide. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacokinetics
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is rapidly absorbed through the gastrointestinal tract. Peak serum levels occur in one to two hours with immediate-release preparations of lithium and within four to five hours with slow-release preparations. Lithium is distributed throughout total body water. Steady state is achieved within four to five days after the last dose change. Lithium is excreted almost exclusively through the kidneys. The half-life is approximately 24 hours in healthy young patients and increases as renal function declines with age. (See
         <a class="local">
          'Pharmacokinetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is contraindicated in patients with significant renal impairment, sodium depletion, dehydration, and significant cardiovascular disease. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         – The starting dose of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is usually 300 mg two or three times daily. The dose should be increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. Dose increases generally occur more frequently at the beginning of treatment, and less often as clinicians approach the target dose. (See
         <a class="local">
          'Lithium dose and serum concentrations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Target serum levels
         </strong>
         – The target serum level for acute phase management and maintenance treatment is generally between 0.8 and 1.2 mEq/L (0.8 and 1.2 mmol/L). Patients who cannot tolerate a level of 0.8 mEq/L (0.8 mmol/L) may respond to a level of 0.6 mEq/L (0.6 mmol/L). (See
         <a class="local">
          'Lithium dose and serum concentrations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring serum levels
         </strong>
         – Levels should generally be measured five to seven days after each dose increase. In addition, a
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         level should be checked if a dose increase is considered and a level has not been measured within the past two weeks. Patients on steady doses should have their levels checked every 6 to 12 months. Lithium levels should be drawn 12 hours after the last dose (12-hour serum trough level) and generally collected in the morning, before the first dose of the day. (See
         <a class="local">
          'Lithium dose and serum concentrations'
         </a>
         above and
         <a class="local">
          'Laboratory tests and monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         <strong>
          toxicity
         </strong>
         – Excessive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         levels can lead to toxicity with severe side effects and multisystem dysfunction, which can be fatal if not recognized. Lithium toxicity is a clinical diagnosis that is confirmed by serum lithium levels. Relatively mild toxicity usually does not occur until serum lithium reaches a level of 1.5 mEq/L (1.5 mmol/L). Levels ≥2.5 mEq/L (2.5 mmol/L) constitute a medical emergency, even in patients who appear relatively asymptomatic. (See
         <a class="local">
          'Lithium toxicity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-drug interactions
         </strong>
         – Multiple medications can alter
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         concentrations. As an example, lithium levels are increased by thiazide diuretics and nonsteroidal anti-inflammatory drugs except
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         . Lithium levels are decreased by potassium-sparing diuretics and
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         . (See
         <a class="local">
          'Drug interactions with lithium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory tests prior to and during
         </strong>
         <strong>
          lithium
         </strong>
         <strong>
          therapy
         </strong>
         – Prior to beginning
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , clinicians should obtain a urinalysis, blood urea nitrogen, creatinine, thyroid function studies, calcium, and pregnancy test for women of childbearing potential; for patients over age 40 years, an electrocardiogram is also obtained. Blood urea nitrogen and creatinine should be checked every two to three months during the first six months of therapy, and every 6 to 12 months thereafter. Thyroid function should be checked once or twice during the first six months, and every 6 to 12 months thereafter. (See
         <a class="local">
          'Laboratory tests and monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         can cause several side effects, including those that involve the kidneys and thyroid gland. In addition, cardiac rhythm disturbances have been described; these almost always occur in patients with preexisting cardiac disease. Severe or a sudden worsening of side effects may be a sign of lithium toxicity. (See
         <a class="local">
          'Managing lithium adverse effects'
         </a>
         above and
         <a class="local">
          'Lithium toxicity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           CADE JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord 2017; 217:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346:f3646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song J, Sjölander A, Joas E, et al. Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder. Am J Psychiatry 2017; 174:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakobsson E, Argüello-Miranda O, Chiu SW, et al. Towards a Unified Understanding of Lithium Action in Basic Biology and its Significance for Applied Biology. J Membr Biol 2017; 250:587.
          </a>
         </li>
         <li class="breakAll">
          Freeman, MP, Wiegand, et al. The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., 2009. p.697.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust N Z J Psychiatry 2012; 46:192.
          </a>
         </li>
         <li class="breakAll">
          Janicak PG, Cutler B. Lithium. In: The Lightest Metals: Science and Technology From Lithium to Calcium, Hanusa T (Ed), John Wiley &amp; Sons, West Sussex 2015.
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li class="breakAll">
          Kamali M, Krishnamurthy VB, Baweja R, et al. Lithium. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.889.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Outhred T. Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding. CNS Drugs 2016; 30:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern S, Santos R, Marchetto MC, et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients' responsiveness to lithium. Mol Psychiatry 2018; 23:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009; 23:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henter ID, de Sousa RT, Zarate CA Jr. Glutamatergic Modulators in Depression. Harv Rev Psychiatry 2018; 26:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang DM, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 2007; 62:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 2010; 128:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Tanious M, Das P, et al. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013; 27:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyoo IK, Dager SR, Kim JE, et al. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 2010; 35:1743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gildengers AG, Butters MA, Aizenstein HJ, et al. Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. Bipolar Disord 2015; 17:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Germaná C, Kempton MJ, Sarnicola A, et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand 2010; 122:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajek T, Cullis J, Novak T, et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord 2012; 14:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Jaramillo C, Vargas C, Díaz-Zuluaga AM, et al. Increased hippocampal, thalamus and amygdala volume in long-term lithium-treated bipolar I disorder patients compared with unmedicated patients and healthy subjects. Bipolar Disord 2017; 19:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell TR, Dima D, Frangou S, Breen G. Telomere Length and Bipolar Disorder. Neuropsychopharmacology 2018; 43:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun YR, Herrmann N, Scott CJM, et al. Global grey matter volume in adult bipolar patients with and without lithium treatment: A meta-analysis. J Affect Disord 2018; 225:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonetti A, Sani G, Dacquino C, et al. Hippocampal subfield volumes in short- and long-term lithium-treated patients with bipolar I disorder. Bipolar Disord 2016; 18:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajek T, Bauer M, Simhandl C, et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med 2014; 44:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Consortium on Lithium Genetics (ConLi+Gen), Amare AT, Schubert KO, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry 2018; 75:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 2016; 387:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.
          </a>
         </li>
         <li class="breakAll">
          Thummel, KE, et al. Design and optimization of dosage regimens: pharmacokinetic data (appendix II). In: Goodman &amp; Gilman's Pharmacological Basis of Therapeutics, 11th ed, Brunton, LL, Lazo, JS, Parker, KL (Eds), McGraw-Hill, New York 2006.
         </li>
         <li class="breakAll">
          MedicinesComplete [Internet database]. Pharmaceutical Press, London, 2010 http://www.medicinescomplete.com (Accessed on September 28, 2010).
         </li>
         <li class="breakAll">
          DRUGDEX® System [Internet database]. Greenwood Village, CO, Thomson Reuters (Healthcare) Inc, 2002-2010. (Accessed September 28, 2010).
         </li>
         <li class="breakAll">
          Alda, M. Pharmacokinetics of lithium. In: Lithium in Neuropsychiatry, Bauer, et al (Eds), Informa UK Ltd, United Kingdom 2006. p.321.
         </li>
         <li class="breakAll">
          Labbate, LA, Fava, et al. Drugs for treatment of bipolar disorders. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.110.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician 2000; 62:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glick ID, Suppes T, DeBattista C, et al. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001; 134:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 2013; 15:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           InstaRead Lithium System. Med Lett Drugs Ther 2005; 47:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauritsen BJ, Mellerup ET, Plenge P, et al. Serum lithium concentrations around the clock with different treatment regimens and the diurnal variation of the renal lithium clearance. Acta Psychiatr Scand 1981; 64:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord 2016; 4:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ott M, Stegmayr B, Renberg ES, Werneke U. Lithium intoxication: Incidence, clinical course and renal function - a population-based retrospective cohort study. J Psychopharmacol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heath LJ, Billups SJ, Gaughan KM, et al. Risk Factors for Utilization of Acute Care Services for Lithium Toxicity. Psychiatr Serv 2018; 69:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jefferson JW. A clinician's guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry 2010; 71:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS. Lithium therapy in bipolar disorder: a balancing act? Lancet 2015; 386:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Gershon S, Outhred T. Lithiumeter: Version 2.0. Bipolar Disord 2016; 18:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009; 23:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. BMC Nephrol 2018; 19:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rej S, Herrmann N, Gruneir A, et al. Association of Lithium Use and a Higher Serum Concentration of Lithium With the Risk of Declining Renal Function in Older Adults: A Population-Based Cohort Study. J Clin Psychiatry 2020; 81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tondo L, Abramowicz M, Alda M, et al. Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. Int J Bipolar Disord 2017; 5:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro HI, Davis KA. Hypercalcemia and "primary" hyperparathyroidism during lithium therapy. Am J Psychiatry 2015; 172:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baek JH, Kinrys G, Nierenberg AA. Lithium tremor revisited: pathophysiology and treatment. Acta Psychiatr Scand 2014; 129:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei P, Ayton S, Appukuttan AT, et al. Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry 2017; 22:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, McAulay C, Gershon S, et al. The Lithium Battery: assessing the neurocognitive profile of lithium in bipolar disorder. Bipolar Disord 2016; 18:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009; 70:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grover S, Ghosh A, Sarkar S, et al. Sexual dysfunction in clinically stable patients with bipolar disorder receiving lithium. J Clin Psychopharmacol 2014; 34:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15317 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18142718" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lithium salts in the treatment of psychotic excitement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28437764" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23814104" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28595491" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29127487" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Towards a Unified Understanding of Lithium Action in Basic Biology and its Significance for Applied Biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29127487" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Towards a Unified Understanding of Lithium Action in Basic Biology and its Significance for Applied Biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391277" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The science and practice of lithium therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391277" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The science and practice of lithium therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391277" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The science and practice of lithium therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391277" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The science and practice of lithium therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27638546" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28242870" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients' responsiveness to lithium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19552485" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922550" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The role of dopamine in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29465478" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Glutamatergic Modulators in Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17572175" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20705090" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23371914" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Potential mechanisms of action of lithium in bipolar disorder. Current understanding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20357761" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25257942" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20560901" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effects of lithium and anticonvulsants on brain structure in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22548899" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28239952" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Increased hippocampal, thalamus and amygdala volume in long-term lithium-treated bipolar I disorder patients compared with unmedicated patients and healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28621334" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Telomere Length and Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28886501" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Global grey matter volume in adult bipolar patients with and without lithium treatment: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27237705" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hippocampal subfield volumes in short- and long-term lithium-treated patients with bipolar I disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23721695" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29121268" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26806518" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11958165" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Practice guideline for the treatment of patients with bipolar disorder (revision).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11011863" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11187420" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16770298" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Drugs for psychiatric disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Adherence to medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23228201" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16247340" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : InstaRead Lithium System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6801927" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Serum lithium concentrations around the clock with different treatment regimens and the diurnal variation of the renal lithium clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27900734" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Lithium side effects and toxicity: prevalence and management strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lithium intoxication: Incidence, clinical course and renal function - a population-based retrospective cohort study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29606078" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Risk Factors for Utilization of Acute Care Services for Lithium Toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20923621" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A clinician's guide to monitoring kidney function in lithium-treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19689501" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26003378" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Lithium therapy in bipolar disorder: a balancing act?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22265699" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Lithium toxicity profile: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28063207" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Lithiumeter: Version 2.0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19453201" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30390660" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32841553" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Association of Lithium Use and a Higher Serum Concentration of Lithium With the Risk of Declining Renal Function in Older Adults: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28480485" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19942149" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Lithium and thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25553494" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hypercalcemia and "primary" hyperparathyroidism during lithium therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23834617" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Lithium tremor revisited: pathophysiology and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400857" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Lithium suppression of tau induces brain iron accumulation and neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27004564" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The Lithium Battery: assessing the neurocognitive profile of lithium in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19689922" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effects of lithium on cognitive performance: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24781439" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Sexual dysfunction in clinically stable patients with bipolar disorder receiving lithium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16750958" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Lithium: clinical considerations in internal medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425293" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20113298" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Treatment of mood disorders during pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8615404" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21088587" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Drug treatment for mood disorders in pregnancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
